Development of Drugs and Technology for Radiation Theragnosis  by Jeong, Hwan-Jeong et al.
eDirect
Nu c l e a r E n g i n e e r i n g a n d T e c h n o l o g y 4 8 ( 2 0 1 6 ) 5 9 7e6 0 7Available online at SciencNuclear Engineering and Technology
journal homepage: www.elsevier .com/locate/netInvited ArticleDevelopment of Drugs and Technology for
Radiation TheragnosisHwan-Jeong Jeong a,1, Byung Chul Lee b,c,1, Byeong-Cheol Ahn d,*, and
Keon Wook Kang e,*
a Department of Nuclear Medicine, Biomedical Research Institute, Chonbuk National University Medical School and
Hospital, 20 Geonjiro Deokjin-gu, Jeonju, Jeollabuk-do, Republic of Korea
b Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang
Hospital, 82 Gumiro 173 Beongil, Bundang-gu, Seongnam, Gyeonggi-do, Republic of Korea
c Center for Nanomolecular Imaging and Innovative Drug Development, Advanced Institutes of Convergence
Technology, 864-1 Iui-dong, Yeongtong-gu, Suwon, Gyeonggi-do, Republic of Korea
d Department of Nuclear Medicine, Kyungpook National University School of Medicine and Hospital,
130 Dongdeok-ro, Jung-gu, Daegu, Republic of Korea
e Department of Nuclear Medicine and Cancer Research Institute, Seoul National University, 101 Daehakro, Jongno,
Seoul, Republic of Koreaa r t i c l e i n f o
Article history:
Received 10 April 2016
Accepted 13 April 2016








Radiation Theragnosis* Corresponding authors.
E-mail addresses: abc2000@knu.ac.kr (B.-
1 H.-J. Jeong and B.C. Lee contributed equa
http://dx.doi.org/10.1016/j.net.2016.04.003
1738-5733/Copyright © 2016, Published by El
the CC BY-NC-ND license (http://creativecoma b s t r a c t
Personalized medicine is tailored medical treatment that targets the individual charac-
teristics of each patient. Theragnosis, combining diagnosis and therapy, plays an impor-
tant role in selecting appropriate patients. Noninvasive in vivo imaging can trace small
molecules, antibodies, peptides, nanoparticles, and cells in the body. Recently, imaging
methods have been able to reveal molecular events in cells and tissues. Molecular imaging
is useful not only for clinical studies but also for developing new drugs and new treatment
modalities. Preclinical and early clinical molecular imaging shows biodistribution, phar-
macokinetics, mechanisms of action, and efficacy. When therapeutic materials are labeled
using radioisotopes, nuclear imaging with positron emission tomography or gamma
camera can be used to treat diseases and monitor therapy simultaneously. Such nuclear
medicine technology is defined as radiation theragnosis. We review the current develop-
ment of drugs and technology for radiation theragnosis using peptides, albumin, nano-
particles, and cells.
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Personalized therapy is a tailored medical treatment targeting
the individual characteristics of each patient. Theragnosis,
combining diagnosis and therapy, plays an important role in
selecting appropriate patients. Pharmacogenomics or gene
panel studies are actively getting into the clinical process to
predict patients' the responses to drugs. However, biopsy-
driven examinations are based on only a small sample of tis-
sue that is removed from a part of the body. These cannot
predict the response of each lesion, especially in cancer pa-
tients. After radionuclide therapy using 131I for thyroid cancer,
whole-body scans are generally performed to evaluate uptakes
and distribution in the body. Lesions can now be more accu-
rately localized and characterizedusing single photonemission
computed tomography/computed tomography (SPECT/CT).
SPECT/CT is a hybrid imaging system that colocalizes radio-
nuclide accumulations on CT-based anatomical structures.We
suggest defining a new term, theragnosis. Combining therapy
and in vivo imaging, theragnosis simultaneously localizes
therapeutic drugs, peptides, genes, or cells through labeling
with radionuclides, fluorescent dye, contrast agents, etc. In this
review, we will focus on current development drugs and tech-
nologies for radiation theragnosis in nuclear medicine.2. Theragnosis using peptides
A variety of nuclear imaging probes led to the development of
molecular imaging using SPECT and positron emission to-
mography (PET). Nuclear imaging techniques, which are based
on the radiolabeling of specific molecular probes using ra-
dioisotopes, can provide insights into the phenotypic func-
tional changes of the disease and the specific biochemical
processes of probes. Using different isotopes labeling directly
or by bifunctional chelators, recently peptide-based radio-
pharmaceuticals have been developed and used as biological
tools for tumor receptor imaging as well as targeted radio-
nuclide therapy. The typical peptide used as nuclear imaging
probes consist of a relatively small number of amino acids (up
to 30) with comparably favorable properties, including high
receptor binding affinity, selective in vivo biological activity,
and rapid pharmacokinetics, but usually do not have immu-
nogenic features. The most widely used radioisotopes for
peptide labeling for diagnostic and radiotherapy purposes are
listed in Table 1.
The first clinical study of 123I-labeled somatostatin deriv-
ative (123I-labeled tyr-3-octreotide) in cancer patients was re-
ported by Krenning et al. [1] in 1989. Subsequently, 111In-
labeled octreotide (111In-Octreoscan, 111In-pentetreotide) was
developed and approved by the U.S. Food and Drug Adminis-
tration (FDA) as the imaging agent for somatostatin receptor-
positive cancer, such as neuroendocrine tumors, mammary
cancer, and small cell lung cancer [2]. In addition, 99mTc-
labeled somatostatin analogs were successfully developed by
the preconjugation of the HYNIC ligand to the peptide and
used in humans [3]. Owing to the development of macrocyclic
chelators such as DOTA, DOTAOC, DOTATOC, DOTAVAP,
DOTATATE, and lanreotide DOTALAN, somatostatin analogsare thus promising theragnosis for peptide receptor imaging
(111In or 68Ga) and radionuclide therapy (90Yo or 177Lu for b
emitters; 213Bi or 225Ac for a emitters) [4e10].
The above results also promote the development of other
peptide radiopharmaceuticals, such as bombesin, neuro-
tensin (NT), cholecystokinin (CCK)/gastrin, exendin, RGD, and
substance P (Table 2).
Bombesin and gastrin-releasing peptide (GRP) share a
highly conserved seven-amino acid C-terminal sequence
(Trp-Ala-Val-Gly-His-Leu-Met-NH2) and also play an impor-
tant role in the growth of different type of cancers [11].
Therefore, 68Ga-labeled Pan-bombesin analog (68Ga-BZH3) was
developed and used to evaluate the impact of peptide re-
ceptors scintigraphy on the diagnosis and the potential ther-
apy [12]. Consistently, new radiolabeled bombesin analogs
have been developed, and their encouraging preclinical re-
sults are applied to clinical oncology [13e17].
NT is a tridecapeptide found in several human cancers
including Ewing sarcoma, meningioma, astrocytoma, and
pancreatic carcinomas [11]. An example for radiolabeled NT,
reported by Franz Buchegger, is the synthesis of 99mTc-NT-XI
containing tricarbonyl 99mTc moiety [18e20]. Despite the
favorable preclinical animal studies of 99mTc-NT-XI, the initial
clinical findings are not promising because of the high
nonspecific uptake of radioactivity in the kidneys.
Based on receptor autoradiographic studies in humans,
CCK and gastrin, which are highly expressed in the intestines
and brain, are highly expressed in 90% of medullary thyroid
carcinomas and in a high percentage of other tumors such as
stromal ovarian cancers, small cell lung cancer, astrocytoma,
gastroenteropancreatic neuroendocrine tumors, and gastro-
intestinal stromal tumors [11,21].
In a comparison of three promising CCK-2 receptor-bind-







DOTA-MG11)], 99mTc-demogastrin 2 showed better detect-
ability and was able to visualize tumor regions in human
medullary thyroid cancer patients better than 111In-DOTA-
CCK and 111In-DOTA-MG11 [22].
The glucagon-like peptide receptor (GLP-1R) is amember of
the G-protein-coupled receptor family, and was found to be
overexpressed in insulinomas, gastrinomas, and medullary
thyroid carcinomas. Exendin-4 consists of 39 amino acidswith
metabolic resistance and shares an approximately 50% ho-
mology with the human GLP-1. For diagnosis and internal
radiotherapy, 111In labeled exendin-4 was developed and
evaluated for its therapeutic efficiency. In particular, 111In
labeled [Lys40(Ahx-DTPA)-NH2]-exendin-4 was able to distin-
guish between benign and malignant insulinomas. Moreover,
111In labeled [Lys40(Ahx-DOTA)-NH2]-exendin-4 is a very
promising peptide radiopharmaceutical for visualizing insu-
linomas and clinically detects pancreatic and ectopic insuli-
nomas [23e25].
One of the most frequently studied peptides are cyclic RGD
(ArgeGlyeAsp) peptides, which have been evaluated for im-
aging integrin avb3 expressed tumors. The vitronectin recep-
tor, integrin avb3 receptor, is known to play an important role
in tumor-induced angiogenesis and tumor metastasis. A
Table 2 e Radiolabeled peptides for cancer theragnosis.
Peptide Target receptor Tumor type
Somatostatin sst2 Neuroendocrine tumors (gastroenteropancreatic tumors), lymphoma,
paraganglioma, carcinoids, breast, brain, renal, small cell lung cancer
Bombesin BB2, GRP-R Breast, prostate, pancreas, gastric, colorectal, small cell lung cancer
Neurotensin NTR1 Ewing sarcoma, astrocytoma, breast, prostate cancer, colon, small cell
lung cancer
Exendin GLP-1 Insulinomas, gastrinomas, pheochromocytomas, paragangliomas and
medullary thyroid carcinomas
RGD Integrin avb3 Glioma, breast cancer, melanomas
Substance P NK1 Glioblastoma, medullary thyroid cancer, small cell lung cancer
BB2, bombesin receptor 2; GLP-1, glucagon-like peptide receptor 1; GRP, gastrin-releasing peptide; NK1, neurokinin type 1; NTR1, neurotensin
receptor 1; sst2, somatostatin receptor 2.
Table 1 e Different radioisotopes and methods for labeling peptides.
Radioisotopes Half-life Labeling methods Application
Fluorine-18 1.83 hr Indirect labeling (prosthetic groups) Diagnosis
Technetium-99m 6.02 hr Direct labeling (SeS bonds) Diagnosis
Chelators (MAG3, DADT, HYNIC)
Rhenium-186/rhenium-188 3.7 d/16.9 hr Same as for technetium-99m Therapy
Iodine-123/iodine-131 13.2 hr/8 d Direct labeling (tyrosine) Diagnosis/therapy
Indirect labeling (BoltoneHunter reagent)
Gallium-68 1.13 hr Chelators (NOTA, DOTA) Diagnosis
Copper-64/copper-67 12.7 hr/2.6 d Chelators (TETA, DOTA, NOTA) Diagnosis/therapy
Indium-111 67.2 hr Chelators (DTPA, DOTA) Diagnosis/therapy
Lutetium-177 160.8 hr Chelator (DOTA) Therapy
Yttrium-90 64.1 hr Chelator (DOTA) Therapy
Bismuth-213 45.6 min Chelator (DOTA) Therapy
Actinium-225 10 d Chelator (DOTA) Therapy
DADT, diaminedithiol; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; HYNIC, 2-hydrazinonicotinic acid; MAG3, mercaptoa-
cetyltriglycine; NOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid; TETA, 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid.
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111In, 123I, 68Ga, 64Cu, 18F, and 90Y. One of the first RGD peptides
to be clinically tested was [18F]Galacto-RGD, which demon-
strated noninvasive quantitative assessment of integrin
expression pattern in patients withmalignant tumors [26]. For
diagnostic imaging or radiotherapy of tumors, [111In/90Y]-
DOTA-E-[c(RGDfK)]2 and [
99mTc/188Re]-IDA-D-[c(RGDfK)]2 were
synthesized and showed favorable biodistribution and in vivo
tissue clearance in mice bearing avb3-positive OVCAR-3 and
U87-MG cells [27,28].
This 99mTc-IDA-D-[c(RGDfK)]2 also offered the strong pos-
sibility of the noninvasive imaging of atherosclerotic plaque in
preclinical studies [29]. In recent studies, RGD-based radio-
labeled hybrid peptides, such as RGD-somatostatin and RGD-
BBN, were developed and showed efficient tumor targeting
with high affinity as compared to the corresponding mono-
metic peptides [30,31].
In order to make up the weak points of inconsistent
expression of somatostatin type 2 receptor limited application
in glioblastoma, radiolabeled substance P derivative was pre-
pared by conjugating the macrocyclic chelators (DTPA or
DOTAGA) to Arg1 of substance P [32,33]. The thymus
expressed enough substance P receptors to allow in vivo
visualization by [111In-DTPA-Argl]esubstance P. a-Emitted
radioisotope labeled substance P, [90Y]-DOTAGAesubstance P,
in particular, was used as the local intratumoral treatment inmalignant glioma patients. [90Y]-DOTAGAesubstance P sub-
stantially inhibited further growth and led to radiation-
induced tumor necrosis [34].3. Theragnosis using albumin
Albumin is the most abundant plasma protein that is synthe-
sized in the liver. Its distribution is primarily intravascular, and
its plasma half-life is 19 days [35]. Its molecular weight is
66.5 kDa and small enough to filter out through glomerulus in
the kidney. Like antibodies, albumin binds to the neonatal Fc
receptor (FcRn), which is expressed in proximal tubular cells,
and is reabsorbed [36]. Albumin is a carrier protein for steroids,
thyroid hormone, retinoids, other lipophilic hormones, and
lipophilic drugs [37]. When Evans blueealbumin complex was
injected into tumor-bearing mice via a tail vein, it gradually
accumulated in the tumor [38]. When Evans blueealbumin
complex was injected into the solid tumor, it was retained in
the tumor for a long period. This phenomenon is now called
the enhanced permeability and retention (EPR) effect on the
tumor. Many nanodrug delivery systems, including liposome,
use this strategy for the passive targeting of tumors.
Radiolabeled human serum albumin (HSA) was used for
the detection of protein losing enteropathy [39]. A 99mTc-HSA
Fig. 2 e PET scan image in a tumor bearing mouse after 46
hours of injection with 64Cu-HSA and 64Cu-
lactosaminated-HSA (64Cu-L-HSA) each. 64Cu-L-HSA
accumulated specifically in HepG2 tissues, whereas 64Cu-
HSA accumulated in HepG2, Hep3B, and HT29 similarly.
HSA, human serum albumin; L, lactosamine; PET, positron
emission tomography.
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distribution [40]. In patients with protein losing enteropathy,
radioactivity accumulated in the abdomen and migrated
distally. 99mTc-HSA was injected in a tumor-bearing mouse,
and radioactivity accumulated slowly in the tumor (Fig. 1). It
has not yet been elucidated why albumin accumulates in the
tumor. Some mechanism other than the EPR effect is sug-
gested. Abraxane is a nanoparticle albumin-bound paclitaxel
and became the first albumin-based antineoplastic agent
approved by FDA. GP60, a 60-kDa glycoprotein expressed on
the plasmamembrane of endothelial cells, binds albumin and
enhances tumor penetration of Abraxane by endothelial
transcytosis [41]. A secreted protein, acidic and rich in
cysteine (SPARC) is highly expressed in malignant cells and
secreted into interstitial space. Because albumin has an af-
finity to SPARC, SPARC may play a role in albumin accumu-
lation in the tumor [42].
For the targeted drug delivery of albumin to the liver or a
hepatocellular carcinoma, galactose residues were introduced
on the surface of albumin [43]. These neoglycoprotein conju-
gates selectively bind to the asialoglycoprotein receptor of he-
patocytes orwell-differentiatedhepatocellular carcinoma cells.
The (6-maleimidocaproyl) hydrazine derivative of doxorubicin
(DOXO-EMCH) was coupled to a thiolated form of lactosami-
nated human albumin (L-HSA). We radiolabeled L-HSA using
64Cu, a positron emitter with a 12.7-hour half-life, via click
chemistry. We made a xenografted mouse model, inoculating
HepG2 (well differentiated hepatocellular carcinoma), Hep3B
(poorly differentiated hepatocellular carcinoma), and HT29
(colon cancer) cells in a mouse. Then, we injected 64Cu-L-HSA
and 64Cu-HSA into tumor-bearingmice via a tail vein.Whenwe
took PET scans, lactosaminated HSA accumulated specifically
in HepG2 tissues, whereas 64Cu-HSA accumulated in HepG2,
Hep3B, and HT29 similarly (Fig. 2). Molecular imaging by PET
scan proved targeted delivery of albumin based drug to tumor
over-expressing asialoglycoprotein receptor. Radiolabeled al-
bumindrugshaveapotential for theragnosis agentsperforming
imaging and targeted therapy simultaneously.4. Theragnosis using nanoparticles
Nanotechnology is the engineering field of handling of mate-
rials and devices with nanometer sizes. Colloidal gold, ironFig. 1 e 99mTc-albumin scan in a tumor bearing mouse.
Radioactivity slowly accumulated in the tumor.oxide nanoparticles, quantum dots (QDs), and nano-sized
liposome are examples of nanoparticles whose size gener-
ally ranges from 1 to 200 nm. This nanotechnology led to a
new aread“nanomedicine,” the application of nanotech-
nology in human healthcare for the diagnosis, monitoring,
treatment, prediction, and prevention of disease. Since the
mid-1990s, when Doxil was approved by FDA, various nano-
constructs have entered the market and have been used in
clinical trials. However, many obstacles exist in applying
nanomaterials to humans. The application of nanotechnology
to medicine offers advanced technology including the early
detection, imaging, treatment of cancers, medical analysis,
drug manipulation, and multifunctionality. Eventually, ad-
vances in nanomedicine could promise greatly improved life
of patients with respect to several diseases. To translate to
clinical use, a deep understanding is needed regarding the
chemical and physical properties of particles and their phar-
macokinetic behaviors in the body, such as biodistribution,
toxicity, and biocompatibility. To understand nanoparticle-
based theragnosis, we first have to learn more about nano-
particles. This review is intended to introduce several nano-
particlesdsuperparamagnetic iron oxide nanoparticle
(SPION), gold nanoparticle (AuNP), QDs, and liposomedwhich
are widely investigated in nanomedicine in terms of molecu-
lar imaging and theragnosis. Besides these nanoparticles,
there are numerous nanosubstances or combinatory nano-
materials using two or three materials, such as chitosan
nanoparticles, and block copolymer nanoparticles, etc. The
medical doctors and researchers who work in the field of
medicine should pay attention to nanotechnology oriented
from engineering to cooperate with engineers and develop
new medical technology.4.1. Superparamagnetic iron oxide nanoparticles
SPIONs contain one or more superparamagnetic iron oxide
cores composed of a mixture of g-Fe2O3 (maghemite) and
Fe3O4 (magnetite) and a biocompatible coating [44]. Two main
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medical applications: (1) SPIO with a mean particle diameter
of 50e100 nm (coating included); and (2) ultrasmall super-
paramagnetic iron oxide (USPIO) nanoparticles with a size
below 50 nm (hydrodynamic size coating included) [45].
Basically, SPIO and USPIO are known as negative contrast
agents because they can significantly enhance T2* relaxation,
resulting in signal void in T2*-weighted images, unlike
gadolinium-based contrast agents, which create a bright
signal in magnetic resonance (MR) images [46]. Interest on
SPIONs has dramatically increased in recent decades.
Because of their low toxicity, large magnetic moments, and
superparamagnetic properties, they have been investigated
for many medical applications such as (1) drug or gene de-
livery, (2) magnetic separation (e.g., in rapid DNA
sequencing), (3) antitumor treatment with magnetic hyper-
thermia therapy, (4) magneto-transfection, and (5) stem cell
tracking, etc. The large surface area of SPIONs has a partic-
ular advantage in its conjugation with targeting moieties,
drug molecules, and imaging probes. Widder et al. [47] used
the first magnetic drug delivery systems. They found that
doxorubicin and magnetite were encapsulated in albumin
microspheres. This led researchers to perform targeted drug
delivery and imaging using magnetic nanoparticles. The
decisive point for high-yield drug delivery using magnetic
nanoparticles is their targeting capabilities. In order to in-
crease the tumor targeting capability, it is essential to attach
targeting moieties (i.e., antibodies, nucleotides, hormones,
and receptor ligands) to the nanoparticle surface. Many
target strategies have been tried to deliver the drug to the
target site. SPIONs have been investigated as site-specific
drug release from SPIONs, targeted prodrug delivery, and
imaging-guided drug delivery (IGDD), etc. For example, Yang
et al. [48] reported the pH-dependent release of doxorubicin
from SPIONs-loaded amphiphilic triblock copolymer nano-
particles. Hwu et al. [49] reported paclitaxol conjugated to the
SPIONs through a phosphodiester bond and then paclitaxol
molecules released from particles by the intracellular phos-
phodiesterase. In the case of IGDD, nanomaterials are being
developed more and more for theragnosis. Theragnosis can
provide noninvasive biodistribution imaging and monitoring
of drug release, so we can predict therapeutic responses and
facilitate therapeutic intervention [50]. Fan et al. [51] synthe-
sized SPIO-conjugated, doxorubicin-loaded microbubbles for
brain tumor drug delivery. In this study, drug release was
controlled by focused ultrasound, and then released SPIO
particles, after destruction, were deposited within brain tu-
mors by a magnetic transducer. The overall process was
monitored by magnetic resonance imaging (MRI). Here, MRI
instruments have a lower sensitivity than fluorescent and
radionuclide imaging. The concept of “platform” can be
introduced to use SPIONs with pros and cons. Coated SPIONs
can be used as a platform conjugated with targeting moiety
and the other imaging probes, such as fluorescent dyes for
optical imaging, and radioisotopes for gamma imaging that
have more sensitivity than an MRI probe [52,53]. The other
method for molecular imaging by using SPIONs is to make
nanoparticles including SPIONs or to make layers containing
iron oxide [54]. These particles can be used in dual or triple
imaging platforms.4.2. Gold nanoparticle
AuNPshave beenused in various biomedical applications such
as diagnosis, treatment of disease, and pharmaceutical drug
delivery. AuNPs have certain characteristics, such as their
facile synthesis, easy surface functionalization, unique optical
properties, and biocompatibility. High-quality, high-yield, and
size controllable colloidal gold can be prepared using the cit-
rate reduction method [55]. AuNPs are detected by X-ray ex-
amination, so these can be used as a theragnosis substance.
The properties of superior light absorption, scattering
(1,000 times higher than organic dyes), and converting into
thermal energy by surface plasmon resonance of AuNPs
quickly found a use in photothermal cancer therapies [56].
When AuNPs absorbed a heating source such as near-infrared
light, the excited electrons (collective coherent oscillation)
return to the ground state, and this rapid relaxation makes
energy in the form of heat, and as a result the surrounding
temperature is simultaneously raised and cancer cells are
destroyed. As mentioned above, this phenomenon can be
used to provide contrast for photoacoustic imaging or photo-
thermal therapy (PTT). Photothermal heating only occurs
surrounding AuNPs, and high temperatures can easily be
localised to reduce the negative side effects of cancer thera-
pies [57]. The temperature rise is primarily related to shape
and concentration, incubation time, laser fluency (power per
unit area), and laser exposure time. Near-infrared light is
more optimal for in vivo therapy of tumors within deep tissues
because of its deep penetration, and minimal absorption of
the hemoglobin and water molecules in tissues. PTT in recent
years have been used with gold nanorods (AuNRs). Recently, a
new nanoparticle platform for PTT was reported. Li et al. [58]
reported a new delivery and photothermal ablation system
based on AuNRs-laden-macrophage (macrophages are Trojan
horses carrying 7-nm-diameter AuNRs). After intratumoral
injection, the bovine serum albumin (BSA)-coated sAuNRs-
laden-macrophages show greatly improved photothermal
conversion almost everywhere in the tumor, resulting in
minimized tumor recurrence rates compared to free BSA-
coated sAuNRs. Piao et al. [59] reported that porous and
hollow-structure AuNPs were coated with red blood cell (RBC)
membrane. RBC-AuNPs exhibit significantly enhanced in vivo
blood retention and circulation and drastically enhanced
tumor uptake when administered systematically, and mice
that received PTT cancer treatment showed 100% survival
over a span of 45 days. Rengan et al. [60] reported on biode-
gradable gold-coated liposome nanoparticles (lipidegold
hybrid material). The combination treatment of this hybrid
with a laser results in a 4.63-fold reduction of the tumor
bioluminescence signal compared with controls.
To increase the sensitivity of detection and the therapeutic
effects of AuNPs, many researchers had been trying to label
with radionuclides such as 111In, 18F, and 177Lu on gold nano-
structures [61e63].
4.3. Quantum dots
QDs are light-emitting colloidal semiconductor nanocrystals
with a coreeshell structure and a diameter typically ranging
from 2 to 10 nm and contains a small finite number of
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1993, Murray et al. [64] developed a simple route to produce
high-quality CdSe QDs using a high-temperature organome-
tallic procedure. After that, tremendous research efforts have
been devoted to fabricating high-quality QDs for applications
in biology andmedicine. QDs have been investigated a little as
a theragnosis agent because of the composite's toxicity.
Recent advances on cadmium-free synthesis have pushed
QDs to become important fluorescent probes for bioimaging
research. In comparison with organic dyes and fluorescent
proteins, QDs offer several unique advantages, such as
tunable emission fromvisible to near-infraredwavelengths by
size and composition. In addition, a large surface area/volume
ratio permits the attachment of a large quantity of target
moieties or drugs, and their excellent stability for long
investigation times are themain advantages of QDs compared
to other fluorescent agents [65]. Targeting moieties on QDs
have been studied with aptamers and antibodies [66,67]. QDs
exert their therapeutic effect as conjugation, inclusion, or
mix-up with drugs containing therapeutic genes [68e70]. New
synthetic techniques such as alloying, core/shell, and doping,
developed in recent years, will likely play key roles in the
future development of tuning the band gap.
4.4. Liposome
Liposomes have been studied as potential drug carriers, but
recently, there has been a focus on their use as an imaging
agent. Liposome has many attractive features as imaging
agents for clinical applications. The surface of a liposome can
be modified easily by adding special ligands for selective tar-
geting and uptake such as transferrin receptors and pancre-
atic adenocarcinoma [68,71]. One field of application for
imaging agents is the lymphatic system. They are ideal for
transport through the lymphatic system because of their size
and biocompatibility. Liposome can also contain imaging and/
or therapeutic substances inside. For example, using these
characteristics of liposome, my colleagues reported a man-
nosylated liposome containing encapsulated indocyanine
green for sentinel lymph nodal optical imaging agent [72]. We
also suggested liposomal nanoparticles as a theragnosis agent
to treat ischemic lesions by delivering angiogenic peptides
into ischemic lesions, as well as by imaging the place where
nanoparticles are accumulated in the body [73,74].5. Theragnosis using cells
Cell-based therapy, the therapy using microbial or human
cellular materials, is a new pharmaceutical frontier [75]. Cells
havemore distinct therapeutic capabilities compared to small
molecule drugs and biologics (e.g., antibodies, hormones,
growth factors), especially in the arena of regenerative medi-
cine. However, cell-based therapy can also be applied to treat
infections, autoimmunity disorders, cancers, metabolic dis-
eases, and tissue degeneration [75,76].
Cells can actively move toward organs that have disorders
or tissues that have injuries by recognizing specific signals for
the lesions, and they have abilities to sense theirmicroenvironments and repair disordered biology or heal
injured tissue [75]. A comprehensive understanding of the
biology of therapeutic cells is essential to harness cell-based
therapy as a strong armor against various intractable diseases.
Theragnosis with cells is drastically improving through the
advancement ofmolecular imaging technologies, which allow
the visual representation, characterization, and quantifica-
tion of biological processes at the cellular and subcellular
levels within intact living organisms [76]. In vivo tracking of
cells is an indispensable technology for the development and
optimization of cell-based therapy by monitoring trans-
planted stem cells or immune cells in preclinical animal and
clinical human models [76,77].
Stem cell therapy has become a promising therapeutic
modality of tissue regeneration for diseases that are irre-
versible (e.g., myocardial infarction, stroke, alopecia) by con-
ventional therapies. The therapeutic cells are believed to be
responsible for growth, wound healing, and replacing cells
that are lost through pathological conditions or daily wear and
tear. The therapeutic effect of the stem cell therapy may be
related to the in vivo survival of therapeutic cells and genera-
tion of target tissue by differentiation of the cells [76].
Direct labeling of therapeutic cells with signal producing
elements (radionuclides, fluorophore, nanoparticles, etc.) can
feasibly visualize the cells in in vivo animal models, which
have a great advantage for basic pathophysiologic and thera-
peutic studies of diseases that are difficult, or impossible, to
perform in humans. However, the direct labeling technique
has critical pitfalls for the purpose of in vivomonitoring of the
labeled cells. Therapeutic cells are able to proliferate after
introduction into the subject; however, the average intensity
of imaging signals from the directly labeled cell is degraded by
the division of the celldthe so-called dilution effect (Fig. 3).
The death of the labeled cell cannot turn off the signals via the
presence of the signal-producing element in the deceased
cells, even after being engulfed by scavenger cells (Fig. 4).
Elution of the signal-producing elements from the cells is
another issue. The limitations permit the use of direct labeling
mainly for short-term and early-phase in vivo monitoring
studies. Indirect labeling of the therapeutic cells using trans-
duction of imaging reporter genes into the cells can resolve
the limitations of direct labeling. Daughter cells from the di-
vision of the transduced therapeutic cells have exactly the
same reporter genes in their nucleus; therefore, signal in-
tensity from the daughter cells should be the same as the
parent therapeutic cells. In addition, the death of parent or
daughter cells will turn off the signals.
Indirect labeling with reporter gene driven by a tissue-
specific promoter can visualize differentiation of stem cells
noninvasively in both in vitro and in vivo models [77,78]. The
reporter gene strategy using a specific promoter system can be
used in high-throughput in vitro screening platforms for
differentiating agents and in assessing in vivo differentiation
of the administered therapeutic stem cells (Fig. 5).
Some therapeutic immune cells, such as natural killer cells
or cytotoxic T cells, can seek and destroy intractable cancers,
which are not responsive to conventional radiation or
chemotherapy because of their innate characteristics. Migra-
tion of the cells to the target cancer is an essential part of the
therapeutic success, and molecular imaging for the
Fig. 4 e Signals from cells directly labeled with signaling elements (fluorophores) persist after death of the cells; however,
signals from cells indirectly labeled cells using reporter genes (fluorescent protein) are turned off after death of the cells.
Fig. 3 e Signal dilution effect by cell division in cells directly labeled with signaling elements (fluorophores), but not in
indirectly labeled cells using reporter genes (fluorescent protein).
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toward cancers; therefore, the therapeutic effects of the cell
for the cancer can be forecast with the imaging.
Other immune cells, such as dendritic cells, have the
ability to present antigens to cells of the adaptive immune
system (T and B cells) in lymphatic tissues, and the thera-
peutic effect of the dendritic cell therapy requires the suc-
cessful migration of the cells to the lymphatic organs;
therefore, the therapeutic effect of the cell can be predicted by
molecular imaging demonstrating in vivomigration of the cells
to the lymphoid organs [79,80].
Therapeutic cells can be engineered to manage disorders
more efficiently and to broaden their applications [75]. The
disease-targeting ability of therapeutic cells can be enhanced
by the modification of the extracellular targeting domain of
the cell, and the effect of the modification can be feasibly
assessed by in vivo molecular imaging by direct or indirect
labeling methods [81].
New nanoparticles or other synthetic delivering agents are
under development to deal with some diseases that areintractable, mainly because of the lack of efficient drug de-
livery strategies that can target diseased areas. However, a
large portion of the new drug-delivering vehicles can still be
sequestered in the reticuloendothelial system. As an alterna-
tive, certain types of cells that are capable of homing to
diseased or injured tissues can be used as unique carriers for
theragnosis agents. For liver injury, mesenchymal stem cells
have a natural tendency to home in on injured areas of the
liver; therefore, the cells can be used as drug delivering bea-
con, and in addition, the mesenchymal stem cells can also
help in the regeneration of the injured liver tissue [82].
Cell-based therapy is emerging as a hope for medicine as a
new pillar of therapeutics to the conventional small molecule
drugs and biologics, and application of the theragnosis strat-
egy usingmolecular imaging techniques to the therapy speeds
up the realization of its clinical applications.
Radiation theragnosis for thyroid cancer using radioiodine
is an old practice but still practical to use. Whole-body scans
following radioiodine therapy enables lesion-by-lesion moni-
toring of treatment. If we radiolabel therapeutic materials or
Fig. 5 e Dual reporter gene system using both neuron specific promoter driven green fluorescent protein (GFP) and cardiac
specific promoter driven red fluorescent protein (RFP) can noninvasively visualize stem cells differentiation in both in vitro
and in vivo environments. Neuronal differentiation of the stem cell makes production of GFP and cardiac differentiation of
the stem cell makes production of RFP instead.
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particles, and cells, they are applicable as theragnosis agents
for various diseases. Radionuclide imaging can also act as a
tool for the development of drugs and therapeutics.Conflicts of interest
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